Patent · US Active

HB-EGF inhibitor derived from the R domain of diphtheria toxin for the treatment of diseases associated with the activation of the HB-EGF/EGFR pathway

US9758552B2 · kind B2 · utility

0Cited by

3References

14Claims

0Family size

Assignee

COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · FR

Inventors

Daniel Gillet · Paris, FR
Benoît Villiers · Alfortville, FR
Sylvain Pichard · Arpajon, FR
Bernard Maillere · Versailles, FR
Alain Sanson · Les Ulis, FR

Key dates

Filing date	Mar 19, 2013
Grant date	Sep 12, 2017
Priority date	—
Expiry date	Apr 19, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y204/02036
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.